To address conflicting reports about the cardiovascular safety of DPP-4 inhibitors, researchers performed a large retrospective cohort study.
CV Events: Safety of Insulin
A study compared mortality and major adverse cardiovascular events in patients with type 2 diabetes prescribed metformin or insulin.
GLP-1 Agonists: Beneficial in Low-Risk Patients?
Do low-risk CVD patients with T2DM experience the same significantly lower all-cause and CV mortality seen in high-risk patients?
Obesity Management: ENDO 2017 Highlights
Could corticosteroid use put your patients at a greater risk of metabolic syndrome?
Clinical Dilemmas in Diabetes
Research presented at ENDO 2017 explored options to reduce complications in patients with diabetes and microalbuminuria and patients with cystic fibrosis.
Endo News Roundup: Diabetes and Cardiovascular Disease
Studies include drug-free remission of T2DM, and the impact of hyperglycemia and hypoglycemia on cardiovascular health.
Evaluate Cardiometabolic Risk in Youth
How well do waist-to-height ratios calculated using NHANES and WHO protocols indicate cardiometabolic risk in youth with diabetes?
Dapagliflozin: All-Cause & Cardiovascular Mortality
Research has shown the beneficial effects of empagliflozin on all-cause and CV mortality. Does the same hold true for another SGLT2 inhibitor?
Statin Therapy with Type 2 Diabetes & Nephropathy
In patients with type 2 diabetes complicated by nephropathy, what is the real life effect of statin therapy on cardiovascular disease prevention?
CV Risks and Diabetes: Puerto Rican Population
Dr. Bobby Lazzara discusses a study looking at certain demographics and cardiovascular complications in a diabetic patient population in Puerto Rico.
Top 10: Endocrinology Network 2016
SGLT2 inhibitors, GLP-1 receptor agonists, insulin, and more – we’ve compiled a list of this year’s most popular articles on Endocrinology Network.
Interesting T2DM: Psychosocial Care & CV, DM Risk
Our December list includes new care guidelines from the ADA, a new indication for an SGLT2i, and effects of PCI on CV, DM risk.
By clicking Accept, you agree to become a member of the UBM Medica Community.